← All indications
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
Drugs by status
Approved for this indication (14)
Phase 4 trials (9)
Phase 3 trials (56)
- alectinib
- 89zr-tlx250
- savolitinib
- carboplatin
- vitespen
- x-82
- gamma-delta t cells
- autologous dendritic cells
- medroxyprogesterone
- vinblastine
- xl092
- naltrexone
- epinephrine
- tremelimumab
- toripalimab
- quavonlimab
- levobupivacaine
- avelumab
- pembrolizumab
- dovitinib
- autologous human tumor-derived hsppc-96
- atezolizumab
- sodium chloride
- capecitabine
- fentanyl
- memantine
- epacadostat
- ketorolac
- ima901
- durvalumab
- +26 more
Phase 2 trials (326)
- incomplete freund's adjuvant
- tandutinib
- ldp
- mipsagargin
- gi-108
- 7hp349
- it-101
- bortezomib
- ioflupane i-123
- tislelizumab
- allogeneic lymphocytes
- tivantinib
- th2 rapa cells
- ags-16m8f
- tak-117
- mk-4280
- Mavorixafor
- regorafenib
- ucb4594
- brivanib alaninate
- a166
- pidilizumab
- F 18-fluoroazomycin arabinoside
- metformin
- propranolol
- ro4929097
- von hippel-lindau peptide vaccine
- car.70/il15-transduced cb-nk cells
- oxaliplatin
- mgn1601
- +296 more
Phase 1 trials (193)
- daratumumab
- amg 172
- VSV-IFNβ-NIS
- hfb200603
- adct-301
- personalized neoantigen vaccine
- incyclinide
- 18f-trx
- vinorelbine
- veliparib
- mgc018
- 177lu-nym096
- hc-5404-fu
- gvax pancreatic cancer vaccine
- fpi-2053
- m8891
- tumour infiltrating lymphocytes
- medi5752
- gevokizumab
- cht101
- Peposertib
- ga-oncocaix
- Numidargistat
- tpst-1120
- dff332
- utomilumab
- cdx-527
- so-c101
- parsaclisib
- azd8701
- +163 more
Other trials (34)
- resca-r8b4
- whey protein
- inactivated influenza vaccine
- ga-nota-rd06
- ga-nota-r8b4
- bifidus regularis
- beractant
- indium in-111
- propofol
- vegfr2
- resca-rd06
- glucose
- sevoflurane
- zr-dfo-rb6
- gabapentin
- zr-dfo-r8b4
- l-glutamine
- calcium lactate
- autologous hematopoietic stem cells
- 62cu-thiosemicarbazone
- fructose
- ketone
- meperidine
- 68ga-p16-093
- beta-hydroxybutyrate
- pacritinib
- zenocutuzumab
- morphine
- 68ga-c1
- pyruvate
- +4 more
Organizations
Organization Involved with Phase 4 Indications (21)
- National Cancer Institute, France
- Kidney Cancer Research Bureau
- University of Paris
- Cantonal Hospital of St. Gallen
- Uppsala University
- Chiron
- Azienda Ospedaliera Antonio Cardarelli
- Bristol-Myers Squibb
- University of Toulouse
- Mario Negri Institute
- National Cancer Institute (NCI)
- Ludwig Maximilians University
- Moscow State University
- University of North Carolina at Chapel Hill
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- University of Bordeaux
- University of Basel
- iOMEDICO AG
- Indiana University
- Université catholique de Louvain
- Case Western Reserve University
Organization Involved with Phase 3 Indications (72)
- SFJ Pharmaceuticals, Inc.
- Loyola University
- Cedars-Sinai Medical Center
- University of Chicago
- State University of New York, Buffalo
- Katholieke Universiteit Leuven
- AEterna Zentaris
- immatics Biotechnologies GmbH
- Incyte
- Aarhus University
- University of Glasgow
- Wilex
- Medical Research Council
- Peking University
- Harvard University
- Hutchison MediPharma
- University of California, San Francisco
- University of Milan
- Ningxia Medical University
- ECOG-ACRIN Cancer Research Group
- Mahidol University
- Kidney Cancer UK
- Radboud University
- Amgen
- University of Oslo
- University of California, Los Angeles
- Cornell University
- HonorHealth Research Institute
- Merck
- TC Biopharm
- +42 more
Organization Involved with Phase 2 Indications (301)
- Driven To Cure
- Cancer Biotherapy Research Group
- University of Colorado, Denver
- NewLink Genetics Inc
- Changhai Hospital
- Genzyme
- Egyptian Foundation for Cancer Research
- AZ Sint-Lucas
- Symphony Capital
- University of Rennes
- Oncotech
- Peter MacCallum Cancer Centre
- Thomas Jefferson University
- Celgene
- ZymoGenetics
- Our Lady of Mercy Cancer Center
- University of Pittsburgh
- Astellas
- Zhejiang University
- Abbott
- The Christie NHS Foundation Trust
- Vanderbilt University
- Clinica Universidad de Navarra
- Immunicum AB
- Hestia Duran i Reynals
- Ospedale di Como
- Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
- Clinical Research Technology S.r.l.
- Sunshine Lake Pharma Co., Ltd.
- Eli Lilly
- +271 more
Organization Involved with Phase 1 Indications (60)
- Corvus Pharmaceuticals, Inc.
- Mirna Therapeutics
- Five Prime Therapeutics
- Cancer Immunotherapy Trials Network
- Biocad
- Five Eleven Pharma, Inc.
- Iwate Medical University
- Arcus Biosciences, Inc.
- SillaJen, Inc.
- Cytheris
- Toray Industries, Inc
- State of Texas
- Inhibrx, Inc.
- Surface Oncology
- AIDS Malignancy Consortium
- Monteris Medical
- Apexigen, Inc.
- University of Alabama, Birmingham
- ARMO BioSciences
- Regeneron
- Accord Research
- University of California, Irvine
- Conquer Cancer Foundation
- Umanis
- Neurocrine Biosciences
- Jennerex Inc.
- Immutep S.A.
- Sichuan Huiyang Life Science and Technology Corporation
- Zhongyuan Union Stem Cell Bio-engineering Corporation
- NanOlogy, LLC
- +30 more
Organization Involved with Other Experimental Indications (6)